drugset / Trial / NCT00812786

Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients

NCT00812786

Phase 4 Completed 42 enrolled University Hospital, Limoges
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The main objective is to develop pharmacokinetic methods for individual dose adjustment of the global immunosuppressive treatment (cyclosporine, tacrolimus, mycophenolate mofetil and everolimus, taking into account the pharmacokinetic interactions), in order to optimise the efficiency and reduce the potentially severe sides effects of these drugs. Forty five heart-transplant patients are to be included in this phase IV study to obtain a minimum of 10 patients treated with tacrolimus-mycophenolate, 10 with cyclosporine-mycophenolate and 20 with everolimus-cyclosporine. Ten to 11 blood samples will be collected within the 8 to 12 hours post-dose in each patient and the immunosuppressive drug concentrations will be measured by LC-MS/MS. The pharmacokinetic models and Bayesian estimators thus developed will provide tools for individual dose adjustment of immunosuppressive drugs simultaneously, at different post-transplant periods, using the area under the concentration-time curve (AUC) estimated using a limited number of time-points (2 or 3).

Timeline

Start
2007-07
Primary completion
2011-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide
Subject Everolimus Small molecule
Subject Mycophenolate Mofetil Small molecule
Subject Tacrolimus Small molecule

Indications

No indication recorded.